4736 Carmustine Carmustine is a cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). 154-93-8 2578 C5H9Cl2N3O2 White powder. 31°C 4000 mg/L (at 25°C) Carmustine causes cross-links in DNA and RNA, leading to the inhibition of DNA synthesis, RNA production and RNA translation (protein synthesis). Carmustine also binds to and modifies (carbamoylates) glutathione reductase. This leads to cell death. Hepatic and rapid with active metabolites. Metabolites may persist in the plasma for several days. Route of Elimination: Approximately 60% to 70% of a total dose is excreted in the urine in 96 hours and about 10% as respiratory CO2. Half Life: 15-30 minutes The oral LD₅₀s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. 2A, probably carcinogenic to humans. (L135) For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas. 2014-09-11T02:04:43Z 2014-12-24T20:26:55Z http://en.wikipedia.org/wiki/Carmustine C06873 3423 DB00262 true OC(=NCCCl)N(CCCl)N=O C5H9Cl2N3O2 InChI=1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11) InChIKey=DLGOEMSEDOSKAD-UHFFFAOYSA-N 214.05 213.007181961 Exogenous Solid 1.53 HMDB14407 CHEMBL513 2480